The global biopharmaceutical CMO & CRO market size is expected to reach USD 37.8 billion by 2025, at a CAGR of 7.7%, according to a new report by Grand View Research, Inc. The market is significantly driven by the growing interest of conventional drug developers in biological therapeutics. At present, outsourcing has become a cost-saving strategy for small to medium sized biomanufacturers, as it helps eliminate the need for establishing expensive specialized facilities or hiring and training personnel.
The decline in R&D productivity and increased development costs has resulted in high pressure on biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has created lucrative opportunities for the Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to accelerate their business operations.
Robustness of venture capital investments is one of the important supportive factors that have created growth opportunities for CMOs. Venture capital funds are considered more reliable than public equity. Increasing availability of venture funds for life sciences is expected to further bolster the growth of CMOs. However, these CMOs and CROs are facing competition from in-house departments of pharmaceutical and biotechnology companies. Several big pharma companies like Novartis announced to keep their biomanufacturing process in-house.
Request a Sample Copy of the Global Biopharmaceutical CMO & CRO Market Research Report @ https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-cmo-cro-market/request/rs1
Mammalian cell line-based bioproduction systems held the largest market share in terms of revenue in 2018. Factors responsible for this estimated share include growth in mammalian system titers and yields. CMOs are engaged in standardizing their mammalian systems, thereby driving the revenue growth of the segment. Contract research service is anticipated to be the fastest growing segment over the forecast period, attributed to increasing investment in research programs for development of novel therapeutics. The CMOs are majorly benefitted by the continuous market expansion of biologics.
Several biopharma companies from U.S. are considering Asian countries for development of pharma products. This is primarily due to the growing costs of R&D in their home country and the presence of low-cost production facilities and cheap labor in Asian countries. The key players are also involved in establishing mutually beneficial alliances with other emerging CMOs to scale up their production capabilities.
Further key findings from the study suggest:
- Mammalian cell line-based bioproduction system accounted for the largest market share in terms of revenue in 2018
- Plant-based expression systems are developed and explored as a cost-effective alternative for the production of large molecules
- Contract manufacturing services accounted for the largest market share owing to the presence of wide range of services from cell line development to final packaging of the product
- In recent times, biologics manufacturing is becoming more specialized, as a result, CMOs have become an integral part of the biologics production strategies of clients, leading to biologics gaining a large share of the biopharmaceutical CMO & CRO market
- North America biopharmaceutical research industry is recognized as a leader in biopharmaceutical innovations, thereby resulting in the large share of this region
- Some key CMOs are Lonza; Boehringer Ingelheim GmbH; Patheon; Samsung BioLogics; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Have Any Query? Ask Our Experts @ https://www.grandviewresearch.com/inquiry/4564/ibb
Grand View Research has segmented the global biopharmaceutical CMO & CRO market on the basis of source, service, product, and region:
Biopharmaceutical CMO & CRO Source Outlook (Revenue, USD Million, 2014 – 2025)
- Mammalian
- Non-mammalian
Biopharmaceutical CMO & CRO Service Outlook (Revenue, USD Million, 2014 – 2025)
- Contract Manufacturing
- Process Development
- Downstream
- Upstream
- Fill & Finish Operations
- Analytical & QC studies
- Packaging
- Contract Research
- Oncology
- Inflammation & Immunology
- Cardiology
- Neuroscience
- Others
Biopharmaceutical CMO & CRO Product Outlook (Revenue, USD Million, 2014 – 2025)
- Biologics
- Monoclonal Antibodies (MAbs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi, & Molecular Therapy
- Others
- Biosimilars
Biopharmaceutical CMO & CRO Regional Outlook (Revenue, USD Million, 2014 – 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- Asia Pacific
- China
- India
- Latin America
- Brazil
- Middle East & Africa
- South Africa
Grasp advance knowledge on Global Biopharmaceutical CMO & CRO Industry through in-depth Blog: https://www.grandviewresearch.com/blog/biopharmaceutical-cmo-cro-market-size
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/biopharmaceutical-cmo-cro-market